Insider · CIK 0001914510

Day Lucy

Reports to the SEC for 1 company · MENLO PARK, CA

sec.gov

Transactions

Companies

Filings

CIK

0001914510

Forms 4 and 5

Insider transactions

18 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-03-19	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)A Award	Chief Financial Officer	AAward	+73.7K sh	—	—	73,665
2026-03-19	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−73.7K sh	—	—	0
2026-03-19	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)A Award	Chief Financial Officer	AAward	+66K sh	—	—	66,000
2026-03-19	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−66K sh	—	—	0
2026-03-19	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)A Award	Chief Financial Officer	AAward	+82.3K sh	—	—	82,300
2026-03-19	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−82.3K sh	—	—	0
2026-02-20	ANTXAN2 Therapeutics, Inc.A Award	Chief Financial Officer	AAward	+38K sh	—	—	118,363
2026-02-20	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)A Award	Chief Financial Officer	AAward	−77K sh	—	—	77,000
2026-01-06	ANTXAN2 Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−5,512 sh	$1.01	−$5,578.144	75,363
2026-01-05	ANTXAN2 Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−3,295 sh	$1.00	−$3,304.885	80,875
2025-02-26	ANTXAN2 Therapeutics, Inc.A Award	Chief Financial Officer	AAward	+46.5K sh	—	—	79,170
2025-02-26	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)A Award	Chief Financial Officer	AAward	−93K sh	—	—	93,000
2025-01-03	ANTXAN2 Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−2,957 sh	$1.34	−$3,965.337	32,670
2024-03-15	ANTXAN2 Therapeutics, Inc.A Award	Chief Financial Officer	AAward	+27.5K sh	—	—	30,627
2024-03-15	ANTXAN2 Therapeutics, Inc.A Award	Chief Financial Officer	AAward	+27.5K sh	—	—	30,627
2024-03-15	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)A Award	Chief Financial Officer	AAward	+55K sh	—	—	55,000
2023-02-15	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)A Award	Chief Financial Officer	AAward	+82.3K sh	—	—	82,300
2022-05-12	ANTXAN2 Therapeutics, Inc. · Stock Option (right to buy)A Award	Chief Financial Officer	AAward	+66K sh	—	—	66,000

Recent filings

Accepted (ET)
Mar 234
Day Lucy0001193125-26-120236
SEC(opens sec.gov)
Feb 234
Day Lucy0001193125-26-064174
SEC(opens sec.gov)
Jan 74
Day Lucy0001193125-26-006771
SEC(opens sec.gov)
Feb 284
Day Lucy0000950170-25-030052
SEC(opens sec.gov)
Jan 74
Day Lucy0000950170-25-003160
SEC(opens sec.gov)
Mar 294/A
Day Lucy0001610717-24-000195
SEC(opens sec.gov)
Mar 184
Day Lucy0001610717-24-000169
SEC(opens sec.gov)
Feb 174
Day Lucy0000899243-23-005558
SEC(opens sec.gov)
May 164
Day Lucy0000899243-22-018276
SEC(opens sec.gov)

Companies

AN2 Therapeutics, Inc.Chief Financial OfficerANTX

Address

C/O AN2 THERAPEUTICS, INC. 1300 EL CAMINO REAL, SUITE 100

MENLO PARK, CA, 94025